Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

Allakos (NASDAQ:ALLK) has dropped ~75% in premarket trading Monday after posting disappointing phase 1 results on AK006 for chronic spontaneous urticaria and deciding to end development. Due to ...

Allakos reports Phase 1 failure, lays off 75% of staff: The biotech said AK006 did not produce a clinical benefit in patients ...

U.S. President Donald Trump has directed federal agencies to assess China's performance under the Phase 1 trade deal that he ...

The FDA has granted fast-track designation to an investigational antisense oligonucleotide to treat individuals with myotonic ...

A live question and answer session will follow the formal presentations. A replay of the call will be available in the ...

Former Deputy National Security adviser Victoria Coates analyzes the implications of the cease-fire deal for Gaza and Israel on ‘Fox & Friends Weekend.’ ...

U.S. President Donald Trump has directed federal agencies to assess China's performance under the Phase 1 trade deal that he ...